Synlogic (SYBX) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Offering details and pricing
Registration statement filed to offer securities from time to time after the effective date, as determined by the registrant.
Securities may be offered on a delayed or continuous basis under Rule 415.
The registration statement is an amendment to Form S-3, filed to include new exhibits.
Management team and governance
Principal Executive Officer and Principal Financial Officer is Mary Beth Dooley.
Board of Directors includes Peter Barrett (Chairman), James Flynn, Edward Mathers, and Richard P. Shea.
Underwriters and syndicate
Legal counsel includes Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Synlogic
- Restructured as a shell after discontinuing clinical programs, with sharply reduced expenses and a $1M net loss.SYBX
Q4 202512 Mar 2026 - Biopharma seeks $150M shelf offering after pivoting to strategic alternatives post-trial halt.SYBX
Registration Filing16 Dec 2025 - Annual Meeting to vote on director, executive pay, and auditor, with strong governance focus.SYBX
Proxy Filing2 Dec 2025 - Net loss narrowed to $2.3M in Q3 2025 amid restructuring and strategic review.SYBX
Q3 202513 Nov 2025 - Annual Meeting to vote on directors, executive pay, new equity plan, and auditor ratification.SYBX
Proxy Filing12 Nov 2025 - Losses narrowed sharply after restructuring and trial discontinuation; strategic review ongoing.SYBX
Q2 20257 Aug 2025 - Lead program ended, costs cut, and strategic options under review with $19.4M cash on hand.SYBX
Q3 202413 Jun 2025 - Q2 net income reached $2.0M after restructuring; $20M cash remains as strategic options are explored.SYBX
Q2 202413 Jun 2025 - Discontinued lead program, restructured operations, and now pursuing strategic alternatives.SYBX
Q4 20249 Jun 2025